Skip to content
Assyro AI
FDA Orange Book · active-ingredient family

Eprosartan mesylate

Eprosartan mesylate: 1 brand, 1 generic; first approved Dec 22, 1997; generic available.

Generic availableHas discontinued products
Generic status & protection

Generic available: 1 ANDA application approved.

Brands (NDA)
1
Generics (ANDA)
1
Listed patents
0
Presentations
5

Brand (NDA) products

Originator applications
  • NDA 02073819973 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    EQ 300MG BASETABLETORALDiscontinued
    EQ 400MG BASETABLETORALDiscontinued
    EQ 600MG BASETABLETORALDiscontinued

Generic (ANDA) products (1)

Abbreviated applications
  • EPROSARTAN MESYLATE
    ANDA 20201220112 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    EQ 400MG BASETABLETORALDiscontinued
    EQ 600MG BASETABLETORALDiscontinued

Listed patents

Orange Book patent file

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Approval history

FDA approval span
First approval
29 yr 1 mo ago
Most recent approval
14 yr 11 mo ago

Approvals span 1997–2011 across 2 FDA applications.

Brand (NDA) 150%
Generic (ANDA) 150%

Eprosartan mesylate: frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.